Atlas Trials

A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer

Clinical trial NCT04958993 · TERMINATED

Trial details

NCT number
NCT04958993
Sponsor
Shandong Cancer Hospital and Institute
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2020-11-12
Primary completion
2021-11-20
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.